Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
Mohamad Shebley, Punam Sandhu, Arian Emami Riedmaier et al. · Clinical Pharmacology & Therapeutics · 2018
This work provides a perspective on the qualification and verification of physiologically based pharmacokinetic (PBPK) platforms/models intended for regulatory submission based on the collective experience of the Simcyp Consortium members. Examples of regulatory submission of PBPK analyses across various intended applications are presented and discussed. European Medicines Agency (EMA) and US Food and Drug Administration (FDA) recent draft guidelines regarding PBPK analyses and reporting are encouraging, and to advance the use and acceptability of PBPK analyses, more clarity and flexibility are warranted.
Cited by 391 works. doi:10.1002/cpt.1013 Open-access PDF
Authors
- Mohamad Shebley
- Punam Sandhu
- Arian Emami Riedmaier
- Masoud Jamei
- Rangaraj Narayanan
- Aarti H. Patel
- Sheila Annie Peters
- Venkatesh Pilla Reddy
- Loeckie De Zwart
- Maud Bénéton
- François Bouzom
- Yuan Chen
- Yumi Cleary
- Christiane Collins
- Gemma L. Dickinson
- Nassim Djebli
- Heidi J. Einolf
- Iain B. Gardner
References
- FACTORS AFFECTING DRUG METABOLISM
- Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children
- Food and drugs
- Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective
- Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
- Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation
- Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy
- A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
- Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions
- The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop